Portal hypertension is a serious complication of advanced liver disease that develops when pressure builds up in the blood vessels carrying blood to the liver. Managing this condition requires a careful combination of approaches aimed at preventing life-threatening complications, improving quality of life, and addressing the symptoms that affect daily living.

When Pressure Builds: Understanding Treatment Goals

The treatment of portal hypertension focuses on managing complications rather than reversing the condition itself, since the underlying cause—most commonly cirrhosis or scarring of the liver—cannot be cured. Cirrhosis causes the smooth inner lining of blood vessels in the liver to become irregular and blocked, creating resistance to blood flow and raising pressure throughout the portal venous system. This system of veins normally carries nutrient-rich blood from digestive organs like the stomach, intestines, pancreas, and spleen through the portal vein into the liver for filtering.

^[1]

When blood cannot flow easily through the scarred liver tissue, the body attempts to compensate by redirecting blood through smaller veins. These alternative pathways cause veins to enlarge and weaken, particularly in the esophagus and stomach, where they form fragile bulges called varices. These swollen veins can rupture and bleed, leading to potentially fatal internal bleeding. Treatment therefore concentrates on three main goals: reducing the elevated pressure in the portal vein, preventing or controlling internal bleeding from varices, and managing fluid buildup in the abdomen.

^[1]

The approach to treating portal hypertension depends heavily on the stage of disease and which complications have developed. Up to 90% of people with cirrhosis already have portal hypertension before they experience any symptoms, and up to 40% already have large varices. The severity of portal hypertension is measured by something called the hepatic venous pressure gradient, or HVPG. A normal reading is 5 millimeters of mercury (mmHg) or less. When the gradient reaches 10 mmHg or higher, it is considered clinically significant portal hypertension, and this is when complications like ascites and bleeding typically begin to occur. At 12 mmHg or higher, the risk of life-threatening events increases substantially.

^[2][10]

Medical societies and expert groups have established guidelines based on decades of clinical trials. These recommendations help doctors decide which treatments to use and when. The treatment plan is always individualized, taking into account not only the pressure measurements but also the patient’s overall liver function, other medical conditions, and personal circumstances.

^[10]

Standard Medical and Procedural Treatments

Standard treatment for portal hypertension has evolved significantly over the past several decades through carefully conducted research studies. The first line of defense typically involves medications and lifestyle changes, while more invasive procedures are reserved for specific situations or when initial treatments prove insufficient.

Medications to Lower Portal Pressure

Non-selective beta-blockers represent the cornerstone of medical therapy for portal hypertension. The two most commonly prescribed are propranolol and nadolol. These medications work by reducing blood flow to the portal vein and decreasing pressure throughout the system. They lower the pressure by causing blood vessels in the digestive organs to constrict slightly and by slowing the heart rate. Beta-blockers are particularly effective for preventing a first episode of bleeding from varices, a strategy known as primary prophylaxis. They are also used to prevent bleeding from happening again after an initial episode, called secondary prophylaxis.

^[11][12]

The standard recommendation is that patients with medium to large varices should be offered treatment with non-selective beta-blockers. For those with smaller varices who also have features suggesting high risk of bleeding—such as severe liver disease or red markings on the varices visible during endoscopy—beta-blockers are also recommended. The dose of these medications is typically adjusted gradually upward to achieve the desired effect while monitoring for side effects like fatigue, shortness of breath, low blood pressure, dizziness, and occasionally sexual dysfunction or weight changes.

^[12]

Some research has suggested that certain statins, particularly simvastatin, may help lower portal pressure and potentially improve liver function. In a small clinical trial conducted in Brazil, over half of patients who received simvastatin showed a clinically meaningful decrease in hepatic venous pressure gradient compared to none in the placebo group. The response was especially notable in those with medium to large esophageal varices and those who had previously experienced variceal bleeding. However, more research is needed before statins become a standard part of portal hypertension treatment.

^[11]

Endoscopic Procedures for Bleeding Control

Endoscopic variceal ligation, often called band ligation or EBL, is a procedure performed through an endoscope—a thin, flexible tube with a camera that is passed through the mouth into the esophagus and stomach. During this procedure, small rubber bands are placed around enlarged veins to cut off their blood supply, causing them to shrink and eventually fall off. This technique is highly effective for both preventing bleeding in high-risk patients and stopping active bleeding when it occurs.

^[12]

For primary prevention of bleeding, endoscopic band ligation is considered equally effective as beta-blockers. Patients may be offered a choice between medication and banding, depending on their preferences, the size of their varices, and whether they can tolerate beta-blockers. For those who have already experienced bleeding, the combination of band ligation plus beta-blockers is generally recommended to prevent recurrence, as this combination is more effective than either treatment alone.

^[12]

An older technique called sclerotherapy involves injecting a blood-clotting chemical directly into or around the varices. While this approach can stop bleeding, it has largely been replaced by band ligation because ligation has fewer complications and better outcomes. Sclerotherapy may still be used in certain situations, particularly for gastric varices (enlarged veins in the stomach) where tissue adhesives or glue-like substances are injected to seal off bleeding vessels.

^[16]

Acute Bleeding Management

When variceal bleeding occurs, it represents a medical emergency requiring immediate intervention. The standard of care combines three approaches: medications to reduce portal pressure and blood flow, endoscopic band ligation to directly stop the bleeding, and antibiotics to prevent infection. Vasoactive drugs such as octreotide (a synthetic version of the hormone somatostatin) or terlipressin are given intravenously to constrict blood vessels and reduce blood flow to the portal system. These medications are started as soon as bleeding is suspected and continued for several days.

^[11][12]

Antibiotics are routinely administered because bleeding episodes increase the risk of serious bacterial infections, which can worsen outcomes. The combination of these three approaches—vasoactive medications, endoscopic therapy, and antibiotics—has dramatically improved survival rates for patients experiencing acute variceal hemorrhage over the past few decades.

^[12]

Managing Ascites

Ascites, the accumulation of fluid in the abdomen, is another major complication of portal hypertension. Initial treatment involves restricting dietary sodium to no more than 2 grams per day and taking diuretics—medications that help the kidneys remove excess fluid. The most commonly prescribed diuretics for ascites are spironolactone and furosemide, often used together. Doctors adjust doses carefully while monitoring kidney function and electrolyte levels, as these medications can cause imbalances in potassium and other important minerals.

^[10]

When ascites does not respond adequately to dietary changes and diuretics, or when fluid reaccumulates quickly after treatment, it is termed refractory ascites. In these cases, patients may require repeated paracentesis procedures, where a needle is inserted through the abdominal wall under ultrasound guidance to drain large volumes of fluid. While paracentesis provides immediate relief from uncomfortable abdominal swelling and pressure, it is time-consuming, can be costly, and carries risks including bleeding at the insertion site, infection, electrolyte imbalances, kidney injury, and rarely, bowel perforation. Additionally, removing large amounts of fluid can lead to circulatory problems.

^[10][19]

The TIPS Procedure

For patients who continue to experience complications despite medication and endoscopic therapy, a more invasive option called transjugular intrahepatic portosystemic shunt, or TIPS, may be recommended. This procedure creates a new pathway for blood flow through the liver. A specialized radiologist inserts a catheter through a vein in the neck, threads it into the liver, and places a small metal tube (stent) that connects the portal vein directly to one of the hepatic veins that drain blood from the liver. This shunt allows blood to bypass the scarred liver tissue, reducing pressure in the portal system.

^[17][21]

TIPS is highly effective for treating refractory ascites and preventing recurrent variceal bleeding. Current guidelines recommend that patients with refractory ascites should be evaluated for TIPS. The procedure can significantly reduce the need for repeated paracentesis and improve quality of life. For patients experiencing severe variceal bleeding that cannot be controlled with standard therapy, TIPS may be performed urgently as a rescue treatment. Some studies have shown that performing TIPS early in certain high-risk patients—before they fail standard treatment—may improve survival.

^[12][17]

However, TIPS is not suitable for everyone. The procedure carries risks, including the possibility of worsening hepatic encephalopathy—a condition where toxins that the liver normally filters build up in the bloodstream and affect brain function, causing confusion, personality changes, and in severe cases, coma. This happens because the shunt allows blood to bypass the liver’s filtering system. Other potential complications include bleeding, infection, shunt malfunction requiring repeated procedures, and heart strain from increased blood flow returning to the heart. Careful patient selection and close monitoring after the procedure are essential.

^[17][19]

Surgical Options and Liver Transplantation

Before TIPS became widely available, surgical procedures to create portosystemic shunts were performed, connecting the portal vein to other veins to reduce pressure. One example is the distal splenorenal shunt (DSRS), which connects the splenic vein to the kidney vein. While effective, these open surgical procedures are now rarely performed because TIPS can achieve similar results with lower immediate risk and without requiring general anesthesia or a large abdominal incision. Surgical shunts may still be considered in select patients who are not candidates for TIPS.

^[14]

Liver transplantation represents the only definitive cure for portal hypertension caused by cirrhosis, as it replaces the diseased liver with a healthy donor organ. For patients with advanced liver disease and complications that are difficult to control, transplantation evaluation should be considered. Even while waiting for a transplant, patients typically continue medical and procedural treatments to manage symptoms and prevent complications. The decision to pursue transplantation involves careful assessment of overall health, disease severity, and the availability of donor organs.

^[13][16]

Emerging Therapies and Clinical Trial Treatments

While standard treatments for portal hypertension have improved outcomes substantially, researchers continue to investigate new approaches that might offer better control of portal pressure, fewer side effects, or benefits for patients who do not respond adequately to current therapies. These investigational treatments are being tested in clinical trials at various stages.

Novel Medications Targeting Portal Pressure

Researchers are exploring several classes of drugs that work through different mechanisms to reduce portal hypertension. One area of investigation involves medications that affect the nitric oxide pathway. Nitric oxide is a substance produced in blood vessel walls that causes vessels to relax and widen. In cirrhosis, excessive nitric oxide production in blood vessels outside the liver contributes to low blood pressure and increased blood flow, which can worsen portal hypertension. Conversely, decreased nitric oxide within the liver contributes to increased resistance to blood flow through the liver. Scientists are studying drugs that might increase nitric oxide production specifically within the liver while decreasing it elsewhere, potentially offering a more targeted approach to lowering portal pressure.

^[10]

Another promising avenue involves statins, beyond the simvastatin research mentioned earlier. Studies suggest that statins may work not only by lowering cholesterol but also by improving liver blood flow and reducing inflammation and scarring. Clinical trials are examining whether different statins, used alone or in combination with standard beta-blocker therapy, can provide additional benefit in reducing portal pressure and preventing complications. These studies are typically Phase II or Phase III trials, meaning they are testing both safety and effectiveness compared to current standard treatments.

^[11]

Medications that target the renin-angiotensin-aldosterone system—the same system affected by some blood pressure medications—are also under investigation. This hormonal system becomes overactive in advanced liver disease and contributes to fluid retention and changes in blood vessel tone that worsen portal hypertension. Researchers are testing whether certain medications that block components of this system might help control ascites and reduce portal pressure when added to standard diuretic therapy.

^[10]

Advanced Endoscopic and Interventional Techniques

New endoscopic approaches are being developed to improve upon standard variceal treatment. One technique being studied is endoscopic ultrasound-guided therapy, where ultrasound imaging helps guide the precise injection of clotting agents or placement of coils directly into varices, particularly gastric varices that are harder to treat with standard banding. This approach may offer more targeted treatment and better control of difficult-to-reach vessels.

An alternative to TIPS called balloon-occluded retrograde transvenous obliteration (BRTO) is used in some centers, particularly in Japan and increasingly in the United States. Instead of creating a shunt, BRTO deliberately blocks off abnormal blood vessels that have formed. This procedure may be particularly useful for certain types of gastric varices. Studies are comparing outcomes between BRTO and TIPS to determine which patients benefit most from each approach. Because BRTO does not create a shunt that bypasses the liver, it may cause less hepatic encephalopathy than TIPS, though it might be less effective for controlling ascites.

^[19]

Biological and Regenerative Approaches

Looking further into the future, researchers are investigating biological therapies aimed at reducing liver scarring or even promoting liver regeneration. These experimental approaches are generally in earlier phases of research, typically Phase I or Phase II trials focusing primarily on safety and initial evidence of effectiveness.

Some clinical trials are examining whether stem cell therapies or growth factors might help damaged livers heal and reduce fibrosis. The theory is that by reducing the amount of scar tissue in the liver, blood flow might improve and portal pressure might decrease. While promising in early animal studies and small human trials, these approaches require much more research before they could become standard treatments.

Other investigations focus on medications that specifically target the molecular pathways involved in liver scarring. These include drugs that interfere with inflammatory signals or block the activation of cells that produce excessive scar tissue. If successful, such treatments might slow or even partially reverse cirrhosis, though this remains a long-term research goal rather than an immediately available option.

Improved TIPS Technology

Even established procedures like TIPS continue to be refined. Newer stent designs and coatings are being tested to reduce the risk of shunt malfunction, which currently requires repeat procedures in some patients. Clinical trials are evaluating whether different stent sizes or designs can maintain effective pressure reduction while minimizing the risk of hepatic encephalopathy. Some studies are testing controlled expansion stents that can be adjusted after placement to fine-tune the amount of blood flow through the shunt, potentially offering a better balance between reducing portal pressure and avoiding complications.

^[17]

Where Trials Are Happening

Clinical trials for portal hypertension and its complications are conducted at medical centers around the world. In the United States, major academic hospitals and liver transplant centers frequently participate in multi-center trials sponsored by pharmaceutical companies or funded by government agencies like the National Institutes of Health. European centers, particularly in Spain, Italy, France, and the United Kingdom, have long been leaders in portal hypertension research. Clinical trials are also increasingly conducted in Asia and Latin America.

Eligibility for clinical trials varies depending on the specific study but generally requires confirmation of cirrhosis and portal hypertension through clinical findings, imaging, or pressure measurements. Many trials have specific requirements regarding liver function, the presence or absence of certain complications, and previous treatments received. Patients interested in exploring clinical trial options can ask their hepatologist or gastroenterologist about available studies, or search clinical trial registries to find trials recruiting in their area.

Most common treatment methods

• Medications for pressure reduction
  • Non-selective beta-blockers (propranolol and nadolol) to lower portal pressure and prevent variceal bleeding
  • Vasoactive drugs (octreotide, terlipressin) given intravenously during acute bleeding episodes
  • Diuretics (spironolactone and furosemide) to manage fluid accumulation in the abdomen
• Endoscopic procedures
  • Endoscopic variceal ligation (band ligation) to prevent and treat bleeding from enlarged veins
  • Sclerotherapy with injection of clotting agents or tissue adhesives, primarily for gastric varices
  • Combination of endoscopic therapy with medications for optimal bleeding control
• Interventional procedures
  • Transjugular intrahepatic portosystemic shunt (TIPS) to create a new blood flow pathway and reduce portal pressure
  • Balloon-occluded retrograde transvenous obliteration (BRTO) for certain types of varices
  • Large-volume paracentesis for fluid removal when diuretics are insufficient
• Surgical interventions
  • Surgical portosystemic shunts such as distal splenorenal shunt in selected patients
  • Liver transplantation as definitive treatment for advanced cirrhosis with portal hypertension
• Supportive care
  • Low-sodium diet (typically under 2 grams per day) to reduce fluid retention
  • Protein restriction in select cases where hepatic encephalopathy is problematic
  • Antibiotic prophylaxis during bleeding episodes and in high-risk situations
  • Management of hepatic encephalopathy with lactulose and other medications